While gardasil and cervarix are currently used to prevent human papilomavirus infection in girls, this new vaccine is designed to spur the body's immune system into action following infection. It includes two strains of the virus most closely linked to cervical cancer and is showing some success in early trials.
The study appears in the journal Science Translational Medicine.
